Locus Biosciences

About:

Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.

Website: http://www.locus-bio.com/

Twitter/X: LocusBio

Top Investors: Hercules Capital, Tencent, Abstract Ventures, Viking Global Investors, Artis Ventures (AV)

Description:

Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.

Total Funding Amount:

$119M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Morrisville, North Carolina, United States

Founded Date:

2015-01-01

Contact Email:

info(AT)locus-bio.com

Founders:

Charles Gersbach, Chase Beisel, Dave Ousterout, Nick Taylor, Paul Garofolo, Rodolphe Barrangou

Number of Employees:

51-100

Last Funding Date:

2022-05-18

IPO Status:

Private

Industries:

© 2025 bioDAO.ai